Hematologic MalignancyNCT07413991
Expressive Writing Program Among Young Adults With Blood Cancer
A study testing Expressive Writing Workshop in people with Hematologic Malignancy, run by Blood Cancer United at 1 site in United States.
Trial summary
The goal of this study is to learn more about an expressive writing workshop among people with blood cancer. The main question it aims to answer is whether and how an expressive writing workshop can impact mental wellness. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematologic Malignancy
- What is being tested?
- Expressive Writing Workshop
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Feb 2026to 30 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient with a hematologic malignancy diagnosis in treatment or after treatment is completed, who is currently between the ages of 18 and 39 (young adult), or the informal caregiver of a young adult blood cancer patient
- Located within the U.S., Canada, or U.S. territories
- Able to read and write in English
Who cannot join
- Located outside of the U.S., Canada, or its territories
- Participant is a minor aged 17 years or below
Trial locations and contacts
1 site in 1 country.
United States1 site
Blood Cancer United
Washington D.C., District of Columbia, 20005
About this study
Official title: An Expressive Writing Program to Support Emotional Wellness Among Young Adults With Hematologic Malignancy
The goal of this study is to learn more about an expressive writing workshop among people with blood cancer. The main question it aims to answer is whether and how an expressive writing workshop can impact mental wellness.
Participants will
- Take part in an online expressive writing workshop for four weeks
- Take three surveys at different times over 12 weeks Researchers will compare changes in mental wellness reported by the participants of the workshop to those who will wait four weeks to start the workshop. After four weeks, the participants who are waiting will start their workshop.
Read the detailed description
The goal of this study is to learn more about an expressive writing workshop among people with blood cancer. The main question it aims to answer is whether and how an expressive writing workshop can impact mental wellness.
Participants will
- Take part in an online expressive writing workshop for four weeks
- Take three surveys at different times over 12 weeks Participants will be randomly assigned to one of two study groups by chance. Group 1 will start the workshop the following week. Group 2 will wait 4 weeks before starting the workshop. The workshop is the same for both groups. Each week, participants will be given a writing prompt and asked to spend at least 15 minutes writing a response. They will be able to share their writing response in a private online community group if they would like, but sharing is not required.
Researchers will then compare changes in mental wellness between group 1 and 2.
- Conditions
- Hematologic Malignancy
- Being tested
- Expressive Writing Workshop
- Keywords
- expressive writing
- Medical subject headings
- Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Expressive Writing WorkshopBehavioural
Group 1 will start the workshop the following week. Group 2 will wait 4 weeks before starting the workshop. There is an equal chance of being placed group 1 or group 2. You cannot choose your study group. The workshop is the same for both groups.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Experimental | Primary Intervention Group Receives: Behavioral: Expressive Writing Workshop |
| Group 2 | Placebo comparator | Wait List Control Group Receives: Behavioral: Expressive Writing Workshop |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mental Wellbeing
Participants' mental wellbeing will be evaluated using the Warwick Edinburgh Mental Wellbeing Scale (WEMWBS), specifically the original 14-item scale developed by researchers at the University of Warwick and the University of Edinburgh in 2007. This self-report questionnaire asks questions about participants' feelings and how they have been functioning over the last two weeks to capture a comprehensive view of their recent mental wellbeing. Participants will rate each question on a 5-point Likert scale, and their responses will be totaled to a mental wellbeing score ranging from 14-70; higher scores indicate greater wellbeing.
Measured: Baseline, 4, and 8 weeks
Perceived Stress
A self-report questionnaire captures whether participants perceive different life situations as overwhelming or uncontrollable. Participants will rate each question on a 5-point Likert scale, and their responses will be totaled to a stress score ranging from 0-40, with higher score indicated more perceived stress.
Measured: Baseline, 4, and 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study start1 Feb 2026
- Primary completion30 Aug 2026 (estimated)
- Study completion30 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematologic MalignancyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Blood Cancer United
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07413991
- Sponsor's protocol ID
- BCU26-01
- Status last verified
- Aug 2026
- First submitted
- 10 Feb 2026
- Last updated
- 13 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Participant data will be shared at the aggregate, deidentified level only.
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Expressive Writing Program to Support Emotional Wellness Among Young Adults With Hematologic Malignancy
- ClinicalTrials.gov ID
- NCT07413991
- Acronym / sponsor ID
- BCU26-01
- Conditions
- Hematologic Malignancy
- Keywords
- expressive writing
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Blood Cancer UnitedUniversity, hospital or other
- Study start
- 1 Feb 2026 (actual)
- Primary completion
- 30 Aug 2026 (estimated)
- Study completion
- 30 Aug 2026 (estimated)
- First posted
- 17 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to learn more about an expressive writing workshop among people with blood cancer. The main question it aims to answer is whether and how an expressive writing workshop can impact mental wellness.
Participants will
- Take part in an online expressive writing workshop for four weeks
- Take three surveys at different times over 12 weeks Researchers will compare changes in mental wellness reported by the participants of the workshop to those who will wait four weeks to start the workshop. After four weeks, the participants who are waiting will start their workshop.
Detailed description
The goal of this study is to learn more about an expressive writing workshop among people with blood cancer. The main question it aims to answer is whether and how an expressive writing workshop can impact mental wellness.
Participants will
- Take part in an online expressive writing workshop for four weeks
- Take three surveys at different times over 12 weeks Participants will be randomly assigned to one of two study groups by chance. Group 1 will start the workshop the following week. Group 2 will wait 4 weeks before starting the workshop. The workshop is the same for both groups. Each week, participants will be given a writing prompt and asked to spend at least 15 minutes writing a response. They will be able to share their writing response in a private online community group if they would like, but sharing is not required.
Researchers will then compare changes in mental wellness between group 1 and 2.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1 | Experimental | Behavioral: Expressive Writing WorkshopPrimary Intervention Group |
| Group 2 | Placebo comparator | Behavioral: Expressive Writing WorkshopWait List Control Group |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patient with a hematologic malignancy diagnosis in treatment or after treatment is completed, who is currently between the ages of 18 and 39 (young adult), or the informal caregiver of a young adult blood cancer patient
- Located within the U.S., Canada, or U.S. territories
- Able to read and write in English
Key exclusion criteria (2 listed)
- Located outside of the U.S., Canada, or its territories
- Participant is a minor aged 17 years or below
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Expressive Writing WorkshopGroup 1 will start the workshop the following week. Group 2 will wait 4 weeks before starting the workshop. There is an equal chance of being placed group 1 or group 2. You cannot choose your study group. The workshop is the same for both groups. | Behavioural | Group 1, Group 2 |
Primary outcome
Mental Wellbeing
Time frame: Baseline, 4, and 8 weeks
Participants' mental wellbeing will be evaluated using the Warwick Edinburgh Mental Wellbeing Scale (WEMWBS), specifically the original 14-item scale developed by researchers at the University of Warwick and the University of Edinburgh in 2007. This self-report questionnaire asks questions about participants' feelings and how they have been functioning over the last two weeks to capture a comprehensive view of their recent mental wellbeing. Participants will rate each question on a 5-point Likert scale, and their responses will be totaled to a mental wellbeing score ranging from 14-70; higher scores indicate greater wellbeing.
Perceived Stress
Time frame: Baseline, 4, and 8 weeks
A self-report questionnaire captures whether participants perceive different life situations as overwhelming or uncontrollable. Participants will rate each question on a 5-point Likert scale, and their responses will be totaled to a stress score ranging from 0-40, with higher score indicated more perceived stress.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2026.
- Individual participant dataSharing planned: No. Participant data will be shared at the aggregate, deidentified level only.
Related trials for Hematologic Malignancy
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Active, not recruitingPhase 3
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Multiple Myeloma
Active, not recruitingPhase 1/2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Expressive Writing Workshop in people with Hematologic Malignancy, run by Blood Cancer United at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mental Wellbeing (time frame: Baseline, 4, and 8 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.